Esophageal Cancer Surveillance and Follow-up

Scope and evidence limitations

Surveillance must be stratified by treatment pathway: Barrett’s esophagus (BE) managed with endoscopic eradication therapy (EET), esophageal squamous cell carcinoma (ESCC) treated by endoscopic resection, and esophageal cancer treated with surgery or definitive chemoradiotherapy. The supplied evidence supports surveillance but does not provide a single, validated timetable applicable to all patients. In particular, the AGA guideline addresses when EET should be used and recognizes that EET has greater potential harms and resource use than surveillance endoscopy, but the supplied abstract does not state the post-EET examination intervals. ^[1]A1c

After endoscopic eradication therapy for Barrett’s esophagus

After EET for BE-related neoplasia, surveillance endoscopy should be continued according to the patient’s baseline histology, completeness of eradication, treatment response, and subsequent biopsy findings. The schedule should follow the AGA guideline’s disease-specific recommendations rather than a generic esophageal-cancer schedule. ^[1]A1c At each examination, the endoscopist should assess the treated esophagus and gastroesophageal junction and obtain targeted biopsies of any visible abnormality; the supplied reference establishes the clinical context for EET and surveillance but does not provide sufficient detail to reproduce exact intervals or biopsy numbers. ^[1]A1c

A patient with persistent or recurrent intestinal metaplasia, dysplasia, or visible neoplasia should not be considered to have completed surveillance. Such findings require reassessment of eradication status and consideration of additional endoscopic treatment or other oncologic management under the AGA pathway. ^[1]A1c

After endoscopic resection of ESCC or other superficial neoplasia

Surveillance endoscopy is recommended after endoscopic resection of ESCC. ^[17]B3b Particular attention is required during the first 24 months, because the cited study specifically defined advanced subsequent ESCC detected within 24 months of the preceding endoscopy as a post-endoscopy advanced lesion. ^[17]B3b This definition is not itself a recommendation for a two-year examination interval; rather, it identifies an interval during which clinically important subsequent lesions may be detected and supports close, risk-adapted endoscopic follow-up. ^[17]B3b

Long-term surveillance remains necessary after endoscopic resection because prospective multicenter data evaluated local recurrence, metastatic recurrence, overall survival, and second primary esophageal cancer in patients with muscularis mucosae or shallow submucosal invasion. ^[73] Five-year overall survival was 92.3% for ESCC and 94.2% for esophageal adenocarcinoma in that cohort, but these favorable outcomes do not eliminate the need to monitor for recurrence or metachronous disease. ^[73] Surveillance intensity should be individualized according to histology, depth of invasion, lymphovascular invasion, margin status, curability of resection, and the presence of synchronous or metachronous lesions; the supplied abstract does not specify interval values for each risk group. ^[73]

After esophagectomy or definitive treatment

Post-treatment follow-up should combine recurrence assessment with evaluation of treatment-related morbidity. Locoregional recurrence can occur after surgery; among patients receiving salvage radiotherapy for postoperative locoregional recurrence, the median disease-free interval before recurrence was 13.5 months. ^[20]C4 This observation supports particularly careful clinical review during the first postoperative years, although it does not establish a universal imaging timetable. ^[20]C4

Follow-up should assess dysphagia, odynophagia, reflux, weight change, nutritional intake, respiratory symptoms, and functional recovery. Dumping syndrome is a recognized postoperative complication, and a systematic review and meta-analysis found substantial variation in its reported prevalence after esophageal-cancer surgery, reflecting heterogeneity among studies. ^[2]A1a A separate postoperative cohort evaluated dumping-related symptoms at predefined time points through 24 months, confirming that symptom surveillance may need to extend beyond the immediate postoperative period. ^[11]B2b

Nutritional and functional surveillance should include weight, dietary tolerance, physical activity, and sarcopenia risk. Sarcopenia is common in patients undergoing esophagectomy and is associated with postoperative outcomes in the available systematic review and meta-analysis. ^[7]B2a A 12-week walking and dietary-education program improved quality-of-life-related outcomes and symptoms with assessments at baseline, 3, 6, and 12 months, supporting structured rehabilitation and quality-of-life review during the first postoperative year. ^[4]A1b

Imaging and symptom-triggered assessment

Routine brain imaging should not be inferred from the available evidence. Brain metastases from esophageal carcinoma are uncommon but clinically serious, and the systematic review identified the need for better evidence to guide neuroimaging surveillance; therefore, brain imaging should be symptom-triggered or risk-adapted rather than automatically scheduled for every survivor. ^[14]B2a

Recurrence surveillance should be coordinated with tumor stage, histology, treatment response, recurrence risk, and symptoms. Recurrence-free survival and event-free survival are being evaluated as surrogate endpoints for overall survival in resectable or definitively treated esophageal cancer, but these methodological studies do not establish examination or imaging intervals for routine clinical follow-up. ^[6]A1a[9]B2b

Practical schedule statement

Use a risk-adapted, multimodal schedule rather than one fixed timetable: early and close endoscopic surveillance after EET or endoscopic resection; continued long-term endoscopic follow-up for recurrence and second primary tumors; regular postoperative clinical, nutritional, and functional review; and symptom- or risk-triggered imaging. Exact intervals should be taken from the applicable disease-specific guideline and multidisciplinary treatment plan because the supplied evidence does not provide enough information to safely specify universal time points. ^{[1]A1c[17]B3b[73]}

Scope and principles

Recurrence after esophageal-cancer treatment may be locoregional, nodal, distant, or disseminated, and early recurrence has been defined in one surgical cohort as recurrence within 1 year after resection. ^[24]A1b The available evidence supports a multimodal strategy combining symptom review and examination with endoscopic, cross-sectional, metabolic, and pathology-based assessment; the supplied references do not establish a single validated surveillance schedule or a universal imaging algorithm. ^{[13]A1b[20]C4[24]A1b}

Clinical assessment and endoscopic detection

New or progressive dysphagia, abdominal symptoms, or obstructive symptoms should prompt evaluation for recurrence or metastatic disease, because unusual metastases can present nonspecifically and may be missed when recurrence is not included in the differential diagnosis. ^[75] Small-bowel metastasis from esophageal squamous cell carcinoma is rare, but the reported systematic review of 23 cases emphasizes that it generally indicates advanced disease and may present with abdominal symptoms or small-bowel obstruction. ^[75]

Endoscopy is central when symptoms or imaging suggest intraluminal or anastomotic disease, particularly after definitive chemoradiotherapy, because locally recurrent lesions may be amenable to salvage treatment. ^[31]C4 Salvage photodynamic therapy has been evaluated for local recurrence after definitive chemoradiotherapy, including lesions exceeding the original trial criteria of ≤1/2 luminal circumference, ≤3 cm longitudinal length, and absence of cervical-esophageal invasion. ^[31]C4 Endoscopic assessment should therefore document lesion location, longitudinal extent, circumferential involvement, and suspected depth of invasion when recurrence is identified. ^[31]C4

Artificial-intelligence-assisted real-time esophagogastroduodenoscopy is an emerging adjunct for lesion recognition. A 2026 systematic review and meta-analysis of randomized trials compared AI-assisted with conventional EGD for upper-gastrointestinal neoplasm detection using neoplasm detection rates and lesions per endoscopy, with subgroup analyses by AI system and pathological type. ^[74] This evidence concerns neoplasm detection rather than recurrence-specific surveillance; AI should therefore be regarded as an adjunct to careful examination and tissue diagnosis, not as a replacement for endoscopist interpretation or biopsy. ^[74]

Cross-sectional and metabolic imaging

Contrast-enhanced CT remains relevant for evaluating suspected local, nodal, and distant recurrence, although the supplied evidence does not define a recurrence-surveillance interval. ^[24]A1b In locally advanced esophageal squamous cell carcinoma treated with trimodal therapy, contrast-enhanced CT radiomics combined imaging-derived and clinical features to investigate prediction of early recurrence, which was categorized as local, distant, lymph-node-positive, or disseminated recurrence. ^[24]A1b Radiomics may improve risk stratification, but predictive modeling before recurrence is not equivalent to diagnostic confirmation; suspicious findings require clinical correlation and, when feasible, endoscopic or image-guided pathological confirmation. ^[24]A1b

For suspected metastatic disease, 18F-FDG-PET/CT was used to identify de-novo oligometastatic disease, defined as ≤5 distant metastases, in a multicenter cohort of esophagogastric cancer. ^[13]A1b The same study categorized management as systemic therapy, local treatment with stereotactic body radiotherapy or metastasectomy, combined local and systemic treatment, or best supportive care, illustrating that detection of limited metastatic recurrence can alter treatment selection. ^[13]A1b PET/CT findings should be interpreted in the context of the primary tumor and other imaging because the cited cohort addresses classification and treatment of oligometastatic disease rather than a formal surveillance test-accuracy question. ^[13]A1b

Diffusion-weighted MRI has been studied in esophageal squamous cell carcinoma during concurrent chemoradiotherapy, with serial apparent diffusion coefficient measurements obtained from treatment initiation through treatment completion and response assessed using RECIST. ^[23]C4 This supports MRI as a potential response-assessment tool, but the cited prospective cohort of 38 patients does not establish DWI as a validated test for post-treatment recurrence detection. ^[23]C4

Pathology, biomarkers, and digital detection

Recurrence should be confirmed histologically whenever feasible, particularly when a focal lesion is accessible or when imaging findings could represent treatment-related change. The cited evidence does not validate p16 methylation, p53-IHC capsule-sponge sampling, or other molecular assays for routine detection of recurrent esophageal cancer. ^{[22]C4[28]B2a} The capsule-sponge EDEN study evaluated minimally invasive sampling with p53-IHC against high-definition endoscopy for early esophageal squamous neoplasia in healthy controls, high-risk individuals with prior head-and-neck cancer, and patients with early-stage neoplasia; it was a prospective proof-of-concept screening/diagnostic study rather than a recurrence study. ^[22]C4 Similarly, the p16 systematic review addressed aberrant methylation in esophageal carcinogenesis and did not establish a surveillance assay for recurrence. ^[28]B2a

Automated electronic-health-record detection may improve ascertainment of recurrence in registries and clinical workflows. A 2026 single-center retrospective study developed a rule-based natural-language-processing algorithm for gastroesophageal adenocarcinoma after R0 gastrectomy or esophagectomy, prioritizing definitive pathology statements and requiring confirmation of imaging-based recurrence. ^[77] This is an information-retrieval tool, not a patient-facing diagnostic test, and its single-center retrospective design limits generalizability. ^[77]

Interpreting outcomes and acting on recurrence

Recurrence-free or disease-free survival is frequently used to measure outcomes, but a 2025 meta-analysis found that these endpoints are only potential surrogates for overall survival in esophageal-cancer trials and should not be treated as direct evidence of an individual patient’s absence of recurrence. ^[25]B2a After recurrence is confirmed, prognosis and treatment depend on site, burden, symptoms, prior therapy, and performance status. Patients with unresectable or recurrent esophageal squamous cell carcinoma may receive immune-checkpoint-inhibitor-based regimens; early tumor shrinkage has been examined as a prognostic factor, while immune-related adverse events have been investigated for associations with outcomes in retrospective cohorts. ^{[29]C4[67]B3b} Salvage radiotherapy is another option for selected postoperative locoregional recurrence; in a retrospective series of 147 patients, treatment included radiotherapy alone or concurrent chemoradiotherapy, with reported outcomes after salvage treatment. ^[20]C4

The cited studies of endoscopic resection, radiofrequency ablation, brachytherapy, and esophageal GIST primarily address treatment efficacy or recurrence-free outcomes rather than diagnostic surveillance and should not be used to define recurrence-detection intervals. ^{[18]B3b[26]B2a[27]B2a[30]B3b} Population-based endoscopic screening and screening-acceptance studies likewise concern detection of primary or precursor disease, not recurrence after treatment. ^{[10]B2a[76][78]}

Survivorship priorities

Survivorship follow-up after esophageal cancer treatment should extend beyond recurrence surveillance to include nutritional status, swallowing and gastrointestinal symptoms, functional capacity, psychological health, social recovery, and patient-reported quality of life (HRQoL). Patients and families identify persistent symptoms and reduced quality of life as important long-term consequences of oesophago-gastric surgery, while conventional follow-up has historically focused primarily on recurrence and survival.^[54]D5 A multidisciplinary survivorship model has therefore been implemented with assessments at 6 and 12 months after esophagectomy, incorporating validated EORTC symptom and HRQoL instruments, functional review, anthropometry, and biochemical screening for micronutrient deficiencies.^[50]D5

Long-term HRQoL assessment is appropriate in disease-free survivors beyond the immediate postoperative period. Studies evaluating patients more than 1–2 years after transthoracic, transhiatal, McKeown, or Ivor Lewis esophagectomy used EORTC QLQ-C30 and QLQ-OG25 instruments to characterize persistent effects of surgical approach and reconstruction.^[48]D5[49]D5 A European multicenter study likewise assessed disease-free patients more than 1 year after treatment to examine the relationship between postoperative complications and subsequent HRQoL.^[53]D5 A scoping review identified preoperative and surgical predictors of postoperative HRQoL across nine studies involving 2,285 patients, supporting early identification of patients likely to require intensified supportive care.^[47]D5

Gastrointestinal and nutritional late effects

Dumping symptoms are a clinically important late consequence of esophageal resection. A prospective cohort study assessed early- and late-onset dumping symptoms at 1 year after surgery and related symptom severity to HRQL, with follow-up at 1.5 years.^[38]B2b Follow-up should therefore ask specifically about postprandial vasomotor or gastrointestinal symptoms and should distinguish symptom intensity, because the study classified early and late dumping as moderate or severe and compared patients with no dumping symptoms.^[38]B2b

Nutritional support should be individualized according to oral intake, weight trajectory, functional status, symptoms, and biochemical findings. A systematic review evaluated patient-reported outcomes associated with surgical, endoscopic, and radiological techniques used to maintain oral or enteral feeding in esophageal cancer, highlighting that the effect of nutritional-support strategies on PROs remains an important survivorship question.^[40]B2a Persistent or recurrent dysphagia warrants evaluation for benign anastomotic or esophageal stricture. In a prospective multicenter study of refractory benign strictures, biodegradable stenting was studied in patients with dysphagia despite at least 5 dilations or at least 1 radial incision and cutting procedure, although the evidence was nonrandomized and single-arm.^[44]B2b

Physical function, frailty, and rehabilitation

Frailty and physical reserve should be assessed before and after treatment, particularly in older adults and patients undergoing major thoracic surgery. Feasibility work has used 6-minute-walk distance, gait speed, hand-grip strength, comorbidity indices, cardiac-risk indices, modified frailty indices, HRQoL questionnaires, and lean psoas area to characterize risk before lung or esophageal surgery.^[45]C4 In a longitudinal study of 131 older patients undergoing esophageal cancer surgery, frailty and HRQoL were measured preoperatively and at 1 week, 1 month, and 3 months postoperatively to examine their evolution and the effect of baseline frailty on recovery.^[43]B3b

Rehabilitation should combine exercise with nutritional and psychosocial support where feasible. A randomized feasibility trial evaluated supervised versus home-based exercise during concurrent neoadjuvant chemotherapy, with identical nutritional and psychosocial support; recruitment, retention, and dropout were primary feasibility outcomes, and cardiopulmonary and functional measures were secondary outcomes.^[39]C4 After surgery, a retrospective study compared multimodal inpatient rehabilitation with conventional pulmonary rehabilitation, with both programs including pulmonary exercises and the multimodal program adding broader physical recovery activities.^[41]B3b A randomized controlled trial also evaluated a 12-week walking and dietary-education program, with outcomes measured at baseline and 3, 6, and 12 months, including QOL, anxiety, depression, rest/activity circadian rhythm, and sleep.^[4]A1b

Psychological, caregiver, and social survivorship needs

Psychological distress should be actively screened and treated. A study of Managing Cancer and Living Meaningfully (CALM) in patients with esophageal cancer and psychological distress reported reductions in distress, anxiety, and depression, together with improved quality of life; the reported benefit persisted at 1 month after the intervention.^[51]D5 Informal caregivers also experience adjustment challenges and supportive-care needs, and a systematic review synthesized qualitative evidence on caregiver experiences in upper gastrointestinal cancers.^[37]B2a

Employment and financial recovery should be discussed as part of survivorship planning. A multicenter cross-sectional study of employed patients scheduled for curative-intent surgery for gastric or esophageal cancer examined resignation between diagnosis and surgery, associated factors, and HRQoL correlates; 4.2% (7/167) resigned before surgery.^[79] Treatment decisions should incorporate patient preferences regarding efficacy, safety, and quality of life, as demonstrated by a Japanese discrete-choice experiment examining preferences for systemic drug treatment.^[52]D5 Patient-engagement initiatives such as the Esophageal Cancer Patient Network aim to integrate patient and caregiver priorities across the research lifecycle, reinforcing the importance of shared decision-making and patient-informed survivorship services.^[55]D5

Treatment-specific late toxicity

Patients treated with radiotherapy, reirradiation, or brachytherapy require individualized assessment for late local symptoms and treatment-related morbidity. A retrospective institutional series described high-dose-rate esophageal brachytherapy used as definitive treatment, boost, reirradiation, or palliation, reflecting heterogeneous indications and the need to interpret late outcomes in treatment context.^[42]C4 Survivorship review should integrate symptoms, nutritional consequences, functional limitations, psychosocial distress, caregiver burden, employment concerns, and patient-defined priorities rather than relying on recurrence status alone.^{[37]B2a[40]B2a[50]D5[54]D5}

Set expectations for follow-up

Explain that follow-up after esophageal-cancer treatment should address both oncologic monitoring and recovery-related concerns, including quality of life, symptoms, sleep, activity, nutrition, and work-related consequences. The evidence supplied here evaluates patient-reported outcomes and employment around treatment; it does not define a specific imaging, endoscopy, or laboratory surveillance schedule. ^{[4]A1b[48]D5[79]}

Patients should be encouraged to report persistent or worsening symptoms promptly rather than waiting for a scheduled visit. Relevant concerns assessed in the available studies include quality of life, anxiety, depression, sleep, daily activity patterns, and esophageal or gastrointestinal symptoms. ^[4]A1b Long-term survivors may continue to experience health-related quality-of-life issues even when they are disease-free and more than 2 years after esophagectomy. ^[48]D5

Encourage activity and dietary support

A 12-week rehabilitation program combining walking exercise with dietary education was evaluated in a two-arm randomized controlled trial involving patients with esophageal cancer. The intervention group received walking and diet education, while the control group received standard care. ^[4]A1b Outcomes were assessed at baseline and at 3, 6, and 12 months, using the EORTC QLQ-C30 and the esophageal-specific EORTC QLQ-OES18 as primary quality-of-life measures. ^[4]A1b

Counsel patients that a structured walking-and-diet approach may be a practical component of recovery support, but individual activity and dietary plans should be adapted to treatment status, postoperative tolerance, nutritional needs, comorbidities, and clinician advice. This approach was studied as a defined rehabilitation program rather than as unrestricted exercise or a replacement for standard follow-up. ^[4]A1b The trial also evaluated anxiety, depression, rest/activity circadian rhythm, and sleep characteristics, supporting discussion of these domains during follow-up. ^[4]A1b

The supplied abstract describes the trial design, intervention, comparator, outcomes, and follow-up schedule but does not provide the numerical results. Therefore, counselling should not promise a particular magnitude or duration of improvement in quality of life, mood, circadian rhythm, or sleep on the basis of this citation alone. ^[4]A1b

Discuss long-term quality of life

For disease-free patients treated with transthoracic or transhiatal esophagectomy for distal esophageal or gastro-esophageal-junction cancer, long-term health-related quality of life was assessed in a tertiary-referral outpatient population with follow-up longer than 2 years. ^[48]D5 Participants completed the EORTC QLQ-C30 and EORTC QLQ-OG25, and the study examined quality-of-life associations with surgical approach, including subgroup analyses involving minimally invasive esophagectomy and neoadjuvant therapy. ^[48]D5

Explain that quality-of-life assessment should remain individualized: the available study specifically investigated differences and associations related to operative approach and treatment context, but the supplied abstract does not report the numerical findings. ^[48]D5 Accordingly, the evidence provided does not support telling an individual patient that transthoracic, transhiatal, minimally invasive, or neoadjuvant-treatment pathways will necessarily produce a particular long-term quality-of-life outcome. ^[48]D5

Address employment and financial concerns

Employment should be discussed early, including the patient’s ability to continue working, need for leave or workplace adjustments, financial pressures, and concerns about returning to employment. In a multicenter cross-sectional study from Japan, 167 employed patients with gastric or esophageal cancer who were scheduled for curative-intent surgery completed questionnaires across nine institutions between September 2022 and March 2024. ^[79]

Among these participants, 4.2% (7/167) resigned from work between cancer diagnosis and surgery. ^[79] The study examined demographic, socioeconomic, employment, and preoperative health-related quality-of-life variables, including the EORTC QLQ-C30 and QLQ-OG25. ^[79] Exploratory modified Poisson regression did not identify statistically significant predictors of resignation in the reported analysis. ^[79]

These findings support proactively asking about employment and offering referral to social work, occupational-health, financial-support, or vocational services when appropriate; they do not establish an individual patient’s risk of resignation or prove that a particular employment intervention prevents job loss. ^[79]

Shared decision-making and safety-netting

Invite patients and caregivers to identify the symptoms and functional goals that matter most to them, then document these concerns for comparison at subsequent visits using validated quality-of-life instruments when available. ^{[4]A1b[48]D5[79]} Reinforce that rehabilitation, nutritional education, symptom review, psychosocial support, and employment counselling complement—not replace—oncologic follow-up and evaluation of new symptoms. ^{[4]A1b[48]D5[79]} The evidence supplied does not provide a disease-recurrence surveillance timetable, so the surveillance plan should be individualized according to the treating team’s assessment and the patient’s treatment history. ^{[4]A1b[48]D5[79]}